Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
B Chronic Lymphocytic Leukemia

First Posted Date: 2011-07-22

Last Posted Date: 2018-01-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT01400685

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2011-06-20

Last Posted Date: 2016-05-17

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 60

Registration Number: NCT01376401

Locations: 🇪🇸
Hospital Universitario La Fe, Valencia, Spain
🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Clínic, Barcelona, Spain

and more 11 locations

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: Akt Inhibitor MK2206
Drug: Bendamustine Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2011-06-09

Last Posted Date: 2017-09-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01369849

Locations: 🇺🇸
Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States
🇺🇸
Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 41 locations

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Pentostatin
Drug: Ofatumumab

First Posted Date: 2011-05-11

Last Posted Date: 2025-04-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01352312

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-04-11

Last Posted Date: 2022-08-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1401

Registration Number: NCT01332968

Locations: 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇦🇺
St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia
🇨🇦
Humber River Hospital, Toronto, Ontario, Canada

and more 180 locations

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma
Chronic Lymphocytic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Adult Solid Neoplasm
Lymphomatous Involvement of Non-Cutaneous Extranodal Site
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Angioimmunoblastic T-Cell Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Other: Pharmacological Study
Biological: Rituximab
Drug: Veliparib

First Posted Date: 2011-03-31

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT01326702

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Phase 1

Completed

Conditions: B-cell Small Lymphocytic Lymphoma Recurrent

Interventions: Drug: TRU-016
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-03-17

Last Posted Date: 2017-06-28

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 12

Registration Number: NCT01317901

Locations: 🇺🇸
Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States
🇺🇸
Site Reference ID/Investigator# 61542, Augusta, Georgia, United States
🇺🇸
Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States

and more 3 locations